Insider Transactions in Q1 2022 at Enanta Pharmaceuticals Inc (ENTA)
Insider Transaction List (Q1 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 21
2022
|
Bruce L A Carter Director |
SELL
Open market or private sale
|
Direct |
6,000
-56.77%
|
$408,000
$68.03 P/Share
|
|
Mar 21
2022
|
Bruce L A Carter Director |
BUY
Exercise of conversion of derivative security
|
Direct |
6,000
+50.0%
|
$150,000
$25.58 P/Share
|
|
Mar 02
2022
|
Nathalie Adda Sr. VP & Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
12,481
-26.3%
|
$873,670
$70.07 P/Share
|
|
Mar 02
2022
|
Nathalie Adda Sr. VP & Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,481
+20.82%
|
$536,683
$43.46 P/Share
|
|
Mar 01
2022
|
Nathalie Adda Sr. VP & Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
24,339
-20.57%
|
$1,703,730
$70.66 P/Share
|
|
Mar 01
2022
|
Nathalie Adda Sr. VP & Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
24,339
+29.09%
|
$1,046,577
$43.46 P/Share
|
|
Feb 14
2022
|
Jay R. Luly President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,355
-0.33%
|
$146,010
$62.49 P/Share
|
|
Feb 14
2022
|
Jay R. Luly President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
8,028
+0.56%
|
-
|
|
Feb 14
2022
|
Paul J Mellett Chief Fin. & Admin Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
958
-1.62%
|
$59,396
$62.49 P/Share
|
|
Feb 14
2022
|
Paul J Mellett Chief Fin. & Admin Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,034
+2.51%
|
-
|
|
Feb 14
2022
|
Yat Sun Or Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
953
-0.28%
|
$59,086
$62.49 P/Share
|
|
Feb 14
2022
|
Yat Sun Or Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,034
+0.44%
|
-
|
|
Feb 14
2022
|
Nathalie Adda Sr. VP & Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
954
-2.65%
|
$59,148
$62.49 P/Share
|
|
Feb 14
2022
|
Nathalie Adda Sr. VP & Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,034
+4.05%
|
-
|
|
Feb 14
2022
|
Nathaniel S. Gardiner Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
957
-2.03%
|
$59,334
$62.49 P/Share
|
|
Feb 14
2022
|
Nathaniel S. Gardiner Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,034
+3.12%
|
-
|
|
Feb 14
2022
|
Tara Lynn Kieffer Chief Product Strategy Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
552
-6.56%
|
$34,224
$62.49 P/Share
|
|
Feb 14
2022
|
Tara Lynn Kieffer Chief Product Strategy Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,616
+8.83%
|
-
|
|
Feb 14
2022
|
Brendan Luu Chief Business Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
489
-5.95%
|
$30,318
$62.49 P/Share
|
|
Feb 14
2022
|
Brendan Luu Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,412
+7.97%
|
-
|
|
Jan 15
2022
|
Jay R. Luly President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,063
+1.4%
|
$110,693
$11.77 P/Share
|
|
Jan 11
2022
|
Nathalie Adda Sr. VP & Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
12,536
-27.59%
|
$877,520
$70.13 P/Share
|
|
Jan 11
2022
|
Nathalie Adda Sr. VP & Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,536
+12.39%
|
$451,296
$36.73 P/Share
|